Arginine adjunctive therapy in XXXX .

@entity1 @entity1906 @entity1017 @entity378 @entity1907
Background. Dietary supplementation has been used as a mechanism to augment the immune system. Adjunctive therapy with L-arginine has the potential to improve outcomes in @entity378 . Methods. In a randomized clinical trial 63 @entity1 with smear-positive @entity1907 in Markazi Province of Iran were given arginine or placebo for 4 weeks in addition to conventional chemotherapy. The final treatment success, sputum conversion, @entity1017 , and clinical symptoms after one and two months were considered as primary outcomes and secondary outcomes were ESR, CRP, and Hg. Data were collected and analyzed with SPSS software (ver. 18). Results. Arginine supplementation reduced constitutional symptoms (P = 0.032) in @entity1 with smear-positive @entity1906 at the end of the first month of treatment. Arginine treated @entity1 had significantly increased BMI at the end of the first and second months of treatment (P = 0.032 and P = 0.04) and a reduced CRP at the end of the first month of treatment (P = 0.03) versus placebo group. Conclusion. Arginine is useful as an adjunctive therapy in @entity1 with @entity378 , in which the effects are more likely mediated by the increased production of nitric oxide and improved constitutional symptoms and @entity1017 . This trial is registered with Clinical Trials Registry of Iran: IRCT201211179855N2.
